This document is an internal Drug Enforcement Administration quality system document. The document is updated periodically and current as of June 21, 2021 and is provided for informational purposes only. Any sensitive, privileged or otherwise protected information has been redacted, to include the redaction of some document in their entirety...

This document is an internal Drug Enforcement Administration quality system document. The document is updated periodically and current as of March 29, 2021 and is provided for informational purposes only. Any sensitive, privileged or otherwise protected information has been redacted, to include the redaction of some document in their entirety...

The 2020 National Drug Threat Assessment (NDTA) is a comprehensive assessment of the threat posed to the United States by the trafficking and abuse of illicit drugs, the diversion and abuse of licit drugs, and the laundering of proceeds generated through illicit drug sales. It also addresses the role domestic...

A comprehensive approach that will target the top drug threat identified by the local DEA division while continuing to focus on drug trafficking, violence, and crime reduction.

The increasing availability of illicit opioids is the most significant drug threat in Pennsylvania. The Philadelphia Field Division (PFD) monitors this threat closely, periodically reviewing multiple data indicators, in conjunction with investigative information, to continually assess the threat, then share analytical findings with stakeholders in federal, state, and municipal governments.

Illicit stimulants, specifically cocaine and methamphetamine, remain a pervasive drug threat in Pennsylvania. PFD offices, state/local law enforcement agencies, and other stakeholders throughout Pennsylvania report persistent increases since 2017 in various indicators that demonstrate availability, such as the total quantity of illicit stimulants seized by law enforcement, identification of seized...

The Drug Enforcement Administration (DEA) Philadelphia Field Division (PFD) is advising law enforcement and public health counterparts of the increased availability of counterfeit controlled prescription drugs (CPDs) – commonly sold as legitimate CPDs with most containing fentanyl/ fentanyl-related compounds (FRC) – in Pennsylvania and Delaware.

While the presence of fentanyl powder (lethal in doses as small as two milligrams) poses a public safety threat, the ingestion of fentanyl via vaping poses a threat of unknown consequences to the user and those nearby.

The PDIP strives to maintain situational awareness of the threat posed by prescription opioids in Pennsylvania, and to share these analyses with stakeholders in federal, state, and municipal governments. In 2013, the PDIP published a Pharmaceutical Threat Assessment for Pennsylvania that found prescription opioid availability and abuse at epidemic levels...

The Drug Enforcement Administration (DEA) Heroin Signature Program (HSP) analyzes hundreds of wholesale-level heroin samples each year to identify the geographic area—Mexico, South America (SA), Southwest Asia (SWA), or Southeast Asia (SEA)—where the samples were manufactured.